Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01168856 · ClinicalTrials.gov registry record
An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens
A clinical trial, sponsored by Hoffmann-La Roche.
- Terminated
- Registry status
- 734
- Enrollment target
NCT01168856 is a clinical trial that was terminated before completion, run by Hoffmann-La Roche. The registered enrollment target is 734 participants.
The verdict
NCT01168856 was terminated before completion, sponsored by Hoffmann-La Roche.
- TERMINATED
- Registry status
- 734 participants
- Enrollment target
Study Summary
This observational long-term follow-up study will assess the persistence of direct acting antiviral (DAA) resistant mutations and the durability of sustained virological response in patients with chronic hepatitis C who have participated in a Roche DAA treatment protocol. Up to 5 scheduled monitoring visits for blood sampling during an observational period of up to 36 months.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 734 participants |
| Start Date | 2010-09 |
| Est. Completion | 2015-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01168856
The ClinicalTrials.gov registry entry for NCT01168856 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 734 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01168856 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01168856 about?
NCT01168856 is a clinical study titled "An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens". This observational long-term follow-up study will assess the persistence of direct acting antiviral (DAA) resistant mutations and the durability of sustained virological response in patients with chronic hepatitis C who have participated in a Roche DAA treatment protocol. Up to 5 scheduled monitorin...
What is the current status of trial NCT01168856?
This trial is currently terminated. The enrollment target is 734 participants. The study started on 2010-09. Estimated completion is 2015-04.
Who is sponsoring clinical trial NCT01168856?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.